Cargando…
Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
BACKGROUND: Basiliximab and anti‐thymocyte globulin are widely used drugs for induction therapy after pediatric heart transplantation. The aim of this study was to determine whether any differences could be observed between basiliximab and anti‐thymocyte globulin, with respect to long‐term mortality...
Autores principales: | Ansari, David, Höglund, Peter, Andersson, Bodil, Nilsson, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859398/ https://www.ncbi.nlm.nih.gov/pubmed/26722127 http://dx.doi.org/10.1161/JAHA.115.002790 |
Ejemplares similares
-
Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023) -
Impact of Induction Immunosuppressants on T Lymphocyte Subsets after Kidney Transplantation: A Prospective Observational Study with Focus on Anti-Thymocyte Globulin and Basiliximab Induction Therapies
por: Kim, Hyung Duk, et al.
Publicado: (2023) -
Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020) -
Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007) -
A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)